GLP-1 Medications and Constipation: Why It Happens and How to Manage It
Constipation affects roughly 1 in 4 people on semaglutide and tirzepatide. Here's why GLP-1 medications slow the gut — and the evidence-based ways to keep things moving.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on June 28, 2026
Our medical review process ensures clinical accuracy and patient safety.
Introduction
Nausea gets most of the attention, but GLP-1 constipation is the side effect that tends to linger. While queasiness usually fades after the first few dose steps, sluggish bowels can persist for as long as the drug keeps your gut in slow motion. In the pivotal STEP 1 trial of semaglutide 2.4 mg, 24.2% of participants reported constipation, more than double the 11.1% seen on placebo.
Evidence: "Gastrointestinal disorders — most commonly nausea, diarrhea, vomiting, and constipation — were the most frequently reported adverse events, occurring in 74.2% of the semaglutide group versus 47.9% of the placebo group." — Wilding JPH, et al. New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2032183
Constipation rarely forces people to quit the way severe nausea can, but it erodes comfort and adherence, and in a small number of cases it escalates into something more serious. Understanding the mechanism makes it far easier to stay ahead of it.
Why GLP-1 Medications Cause Constipation
Constipation on a GLP-1 drug is not a coincidental side effect — it is a direct extension of how the medication works. The same braking action that curbs appetite and flattens post-meal glucose spikes also slows the journey of food through your digestive tract.
The motility slowdown
GLP-1 receptors line the entire gastrointestinal tract, from the stomach to the colon, and they connect to the enteric nervous system that orchestrates gut movement. Activating them dampens peristalsis, the wave-like muscle contractions that push contents downstream. Gastric emptying slows first and most dramatically, but transit through the small bowel and colon slows too. When stool spends longer in the colon, more water is reabsorbed from it, leaving it harder, drier, and more difficult to pass.
Evidence: "GLP-1 receptor agonists slow gastric emptying and reduce upper gastrointestinal motility; this delay is the dominant mechanism behind the class's gastrointestinal effects and underlies symptoms ranging from early satiety to altered bowel transit." — Jalleh RJ, et al. Journal of Clinical Endocrinology & Metabolism. 2025. DOI: 10.1210/clinem/dgae719
Less food, less fiber, less water
The slowdown is only half the story. GLP-1 medications work by making you eat substantially less, and lower food volume means lower fiber intake — the bulk that normally stimulates the colon and gives stool its form. Many people also drink less when their appetite is suppressed, and reduced fluid intake compounds the dryness. The result is a perfect setup for constipation: slower transit, less bulk, and less water, all at once. This is why management hinges as much on what you add back (fiber and fluid) as on any medication.
How Common Is It?
Constipation is consistently the second or third most reported gastrointestinal effect across the major obesity trials, trailing nausea and roughly tracking with diarrhea. Rates climb with dose and with the more potent dual agonists, though tirzepatide's constipation numbers sit somewhat lower than semaglutide's in head-to-head context.
| Medication (trial) | Constipation rate | Placebo |
|---|---|---|
| Semaglutide 2.4 mg — Wegovy (STEP 1) | 24.2% | 11.1% |
| Liraglutide 3.0 mg — Saxenda (SCALE) | ~20% | ~9% |
| Tirzepatide 5–15 mg — Zepbound (SURMOUNT-1) | 12–17% | 5.8% |
Evidence: "Constipation was reported by approximately 20% of participants receiving liraglutide 3.0 mg versus about 9% on placebo, ranking among the most common gastrointestinal adverse events in the SCALE program." — Pi-Sunyer X, et al. New England Journal of Medicine. 2015. DOI: 10.1056/NEJMoa1411892
In the SURMOUNT-1 trial of tirzepatide, gastrointestinal events including constipation were mostly mild to moderate and clustered during dose escalation, the same pattern that makes slow, patient titration the single most effective preventive tool.
Evidence: "Gastrointestinal adverse events, including constipation, were predominantly mild-to-moderate in severity and occurred primarily during dose escalation rather than at maintenance doses." — Jastreboff AM, et al. New England Journal of Medicine. 2022. DOI: 10.1056/NEJMoa2206038
When It Starts and How Long It Lasts
Unlike nausea, which typically announces itself within days of starting or stepping up a dose, constipation often builds more gradually over the first one to two weeks at a new dose. It tends to be most stubborn during the titration phase, when the gut is adapting to a higher level of receptor activation. For many people it eases once they reach a stable maintenance dose and dial in their fiber and fluid habits. For others — particularly those on the highest doses or prone to slow transit at baseline — it remains a background issue that needs ongoing management rather than a temporary one that resolves on its own.
If you also struggle with nausea early on, our guide to managing GLP-1 nausea covers the titration and meal strategies that help both symptoms at once, since they share the same root cause.
How to Manage GLP-1 Constipation
The good news is that GLP-1 constipation responds well to a structured, stepwise approach. Clinical guidance for this drug class recommends starting with diet and hydration, then layering in osmotic agents before reaching for stimulant laxatives.
Evidence: "For constipation, increasing dietary fiber and fluid intake and encouraging physical activity are recommended first-line; osmotic laxatives such as macrogol can be added when lifestyle measures are insufficient." — Wharton S, et al. Postgraduate Medicine. 2022. DOI: 10.1080/00325481.2021.2002616
Step 1: Fluid and fiber
Aim for consistent hydration — a practical target is around 2 liters (about 64 oz) of water daily, more in heat or with exercise. Build fiber back gradually toward 25–35 grams per day from vegetables, legumes, fruit, and whole grains. If diet alone falls short, a soluble fiber supplement such as psyllium husk (5–10 g daily) is the best-evidenced option, but two rules matter: always take it with a full glass of water, and separate it from your other oral medications. Fiber without enough fluid can make constipation worse, not better. Our overview of fiber supplements for weight loss breaks down the differences between psyllium, glucomannan, and inulin.
Step 2: Magnesium and osmotic laxatives
When food and fluid are not enough, osmotic agents that draw water into the bowel are the next step and are well suited to long-term use. Common options include polyethylene glycol (macrogol/MiraLAX), magnesium citrate or magnesium oxide, and lactulose. Many people find that magnesium does double duty, since it is gentle and easy to titrate. Stimulant laxatives such as senna or bisacodyl can break a stubborn episode but are better reserved for occasional rescue use rather than daily reliance.
Step 3: Movement and meal timing
Physical activity stimulates colonic motility, so even a daily walk helps counter the GLP-1 slowdown. Eating smaller, more regular meals rather than one or two large ones keeps the gut engaged, and the natural urge to go is strongest after meals — honoring that signal rather than postponing it prevents stool from drying out further.
| Strategy | What to do | When to use |
|---|---|---|
| Hydration | ~2 L water/day, more with exercise | Daily, from day one |
| Dietary fiber | 25–35 g/day; add psyllium 5–10 g if needed | Daily, increase gradually |
| Magnesium | Citrate or oxide, titrate to effect | When fiber/fluid insufficient |
| Osmotic laxative | Polyethylene glycol (macrogol) | Persistent constipation |
| Stimulant laxative | Senna or bisacodyl | Occasional rescue only |
| Movement | Daily walk or light activity | Daily |
Red Flags: When to Seek Care
Ordinary GLP-1 constipation is uncomfortable but benign. Rarely, the same motility braking can progress to a near-standstill of the bowel — ileus or, in extreme cases, bowel obstruction — which is a medical emergency. The FDA added a warning about ileus to the semaglutide label after post-marketing reports, and slowed transit is the plausible link. Seek prompt medical attention for severe or worsening abdominal pain and bloating, persistent vomiting, inability to pass stool or gas for several days, or a hard, distended abdomen. People with a history of bowel obstruction, gastroparesis, or chronic constipation should flag this to their prescriber before starting, since they sit at higher baseline risk. For more on the upper-gut version of this slowdown, see our explainer on GLP-1 medications and gastroparesis.
Key Takeaways
- Constipation affects roughly 20–25% of people on semaglutide and liraglutide and 12–17% on tirzepatide, making it one of the most common GLP-1 side effects after nausea.
- It is a direct consequence of the drug's mechanism: slowed gut motility plus reduced food, fiber, and fluid intake combine to harden and stall stool.
- Symptoms are usually worst during dose escalation and often ease at a stable maintenance dose with good fiber and hydration habits.
- Management is stepwise — fluid and fiber first, then magnesium or osmotic laxatives such as polyethylene glycol, with stimulant laxatives reserved for rescue.
- Severe abdominal pain, persistent vomiting, or an inability to pass stool or gas are red flags for ileus or obstruction and warrant urgent medical care.
References
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). New England Journal of Medicine. 2015;373(1):11-22. DOI: 10.1056/NEJMoa1411892
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038
Jalleh RJ, Plummer MP, Marathe CS, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. Journal of Clinical Endocrinology & Metabolism. 2025;110(1):1-15. DOI: 10.1210/clinem/dgae719
Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine. 2022;134(1):14-19. DOI: 10.1080/00325481.2021.2002616
Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2416394
Last updated: 2026-06-28 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.